QQ客服 官方微博 反馈留言

浏览/检索结果: 共6条，第1-6条 帮助 限定条件 发表日期：2021    专题：上海药物研究所    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Advancing COVID-19 diagnosis with privacy-preserving collaboration in artificial intelligence 期刊论文 NATURE MACHINE INTELLIGENCE, 2021, 卷号: 3, 期号: 12, 页码: 1081-1089 作者:  Bai, Xiangd;  Wang, Hanchen;  Ma, Liya;  Xu, Yongchao;  Gan, Jiefeng 收藏  |  浏览/下载：52/0  |  提交时间：2022/01/18 ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker 期刊论文 SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 卷号: 6, 期号: 1, 页码: 9 作者:  Chen, Yuning;  Zhang, Ya-Nan;  Yan, Renhong;  Wang, Guifeng;  Zhang, Yuanyuan 收藏  |  浏览/下载：67/0  |  提交时间：2021/11/04 Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 9 作者:  Wang, Lin;  Wu, Yan;  Yao, Sheng;  Ge, Huan;  Zhu, Ya 收藏  |  浏览/下载：86/0  |  提交时间：2021/11/04 SARS-CoV-2  natural products  virtual screening  spike protein  protein-protein interaction modulators   SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target 期刊论文 CELL RESEARCH, 2021, 页码: 14 作者:  Xia, Bingqing;  Shen, Xurui;  He, Yang;  Pan, Xiaoyan;  Liu, Feng-Liang 收藏  |  浏览/下载：78/0  |  提交时间：2021/08/17 Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS 期刊论文 CHINESE JOURNAL OF NATURAL MEDICINES, 2021, 卷号: 19, 期号: 6, 页码: 473-480 作者:  Wei Wen-Long;  Wu Shi-Fei;  Li Hao-Jv;  Li Zhen-Wei;  Qu Hua 收藏  |  浏览/下载：20/0  |  提交时间：2021/08/17 Huashi Baidu prescription  Corona virus disease 2019  Characterization of chemical constituents  ELISA   Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial 期刊论文 FRONTIERS OF MEDICINE, 2021, 页码: 14 作者:  Ni, Li;  Wen, Zheng;  Hu, Xiaowen;  Tang, Wei;  Wang, Haisheng 收藏  |  浏览/下载：60/0  |  提交时间：2021/08/17 COVID-19  SARS-CoV-2  Shuanghuanglian oral liquid  clinical trial